Intranasal Oxytocin Investigated for Antipsychotic Effects in Schizophrenia Patients

Schizophrenia is a chronic and severe mental disorder characterized by positive, negative, and cognitive symptoms. Despite adequate treatment with current antipsychotic medications, many patients experience persistent residual symptoms, particularly affecting social cognition and functional outcomes. This gap highlights the need for novel adjunctive therapies. Oxytocin, a neuropeptide known for its role in social bonding, trust, and anxiety reduction, has emerged as a candidate due to its potential to modulate social behavior and emotional processing, which are often impaired in schizophrenia.

This study was a two-week double-blind, placebo-controlled, parallel-design trial comparing intranasal oxytocin versus intranasal placebo. The study enrolled 14 patients with schizophrenia who had residual symptoms despite being on stable, adequate antipsychotic medication. Participants received daily intranasal administration of either oxytocin or placebo. The primary objective was to assess the efficacy of intranasal oxytocin in improving symptoms, though specific outcome measures beyond 'improve symptoms' were not detailed in the provided abstract. An optional two-week open-label extension was offered to all participants.